- Home
- PSHG vs NXTC Comparison
PSHG vs NXTC Comparison
Compare PSHG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- NXTC
- Stock Information
- Founded
- PSHG 2010
- NXTC 2015
- Country
- PSHG Greece
- NXTC United States
- Employees
- PSHG N/A
- NXTC N/A
- Industry
- PSHG Marine Transportation
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- NXTC Health Care
- Exchange
- PSHG Nasdaq
- NXTC Nasdaq
- Market Cap
- PSHG 21.4M
- NXTC 23.0M
- IPO Year
- PSHG N/A
- NXTC 2019
- Fundamental
- Price
- PSHG $1.72
- NXTC $0.79
- Analyst Decision
- PSHG Strong Buy
- NXTC Strong Buy
- Analyst Count
- PSHG 1
- NXTC 2
- Target Price
- PSHG $6.50
- NXTC $4.00
- AVG Volume (30 Days)
- PSHG 60.3K
- NXTC 201.3K
- Earning Date
- PSHG 03-06-2025
- NXTC 11-07-2024
- Dividend Yield
- PSHG N/A
- NXTC N/A
- EPS Growth
- PSHG N/A
- NXTC N/A
- EPS
- PSHG 1.51
- NXTC N/A
- Revenue
- PSHG $89,608,000.00
- NXTC N/A
- Revenue This Year
- PSHG N/A
- NXTC N/A
- Revenue Next Year
- PSHG N/A
- NXTC N/A
- P/E Ratio
- PSHG $1.14
- NXTC N/A
- Revenue Growth
- PSHG N/A
- NXTC N/A
- 52 Week Low
- PSHG $1.61
- NXTC $0.76
- 52 Week High
- PSHG $2.58
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- PSHG 42.17
- NXTC 36.33
- Support Level
- PSHG $1.75
- NXTC $0.76
- Resistance Level
- PSHG $1.92
- NXTC $0.83
- Average True Range (ATR)
- PSHG 0.10
- NXTC 0.07
- MACD
- PSHG -0.01
- NXTC 0.01
- Stochastic Oscillator
- PSHG 8.00
- NXTC 14.87
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.